|
Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >
Pregabalin Attenuates Carboplatin-Induced Akathisia-Like Neuropathy: A Novel Case Report
| Title: | Pregabalin Attenuates Carboplatin-Induced Akathisia-Like Neuropathy: A Novel Case Report |
| Authors: | Saito, Yoshitaka Browse this author →KAKEN DB | | Takekuma, Yoh Browse this author →KAKEN DB | | Furuta, Megumi Browse this author →KAKEN DB | | Sugawara, Mitsuru Browse this author →KAKEN DB |
| Keywords: | Chemotherapy-induced peripheral neuropathy | | Akathisia | | Restless legs syndrome | | Pregabalin | | Carboplatin |
| Issue Date: | 4-Oct-2021 |
| Publisher: | Karger |
| Journal Title: | Case reports in oncology |
| Volume: | 14 |
| Issue: | 3 |
| Start Page: | 1418 |
| End Page: | 1421 |
| Publisher DOI: | 10.1159/000518776 |
| Abstract: | Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most serious adverse effects of chemotherapy. We experienced carboplatin (CBDCA)-induced akathisia-like CIPN, which was significantly attenuated by pregabalin administration, and report its treatment. A man in his 40s was administered CBDCA + pemetrexed (PEM) as the third-line treatment for recurrent malignant pleural mesothelioma. He rarely experienced mild akathisia- like symptoms on his feet before the diagnosis. The patient claimed that he exhibited mild degradation of the symptoms in the previous cisplatin (CDDP) + PEM treatment without the need for pharmacotherapy. Symptoms notably worsened approximately 7 days after the first cycle of CBDCA + PEM and did not disappear. Furthermore, symptoms worsened during the daytime and became milder at night. Lorazepam (0.5 mg) was administered 3 times a day from day 14 but was not effective. Finally, we evaluated the symptoms to be derived from CBDCA-induced neuropathy as he experienced the same symptoms in CDDP + PEM and did not have suspicious pathology or medicines for akathisia development. We decided to administer 75 mg pregabalin twice daily, resulting in significant symptom improvement. He also complained that he felt the symptoms 10 h after the previous pregabalin dose, suggesting that pregabalin was effective, and its effect weakened or disappeared as time progressed. Akathisia-like symptoms caused by CBDCA-induced CIPN are rare, but they significantly reduce the quality of life. Pregabalin was significantly effective in this case; therefore, we suggest that a detailed symptom interview and selection of the medicine, based upon the action mechanism, are necessary. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/85156 |
| Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
